Will blocking IL-17A help treat kidney disease?
Dr. Ghali, Bentham Science Publishers
Since the discovery of the proinflammatory cytokines, interleukin (IL)-17A and IL-17F in the early 1990s, many immune cells have proven to be a source of these cytokines, including some T helper cells, now called Th17 cells. Recent human trials of biological therapies targeting IL-17A, components of its receptor or precursor cytokines, have significantly improved clinical disease in some conditions where Th17 cells are implicated -- particularly psoriasis.
We have reviewed the research that indicates that IL-17A/F and Th17 cells contribute to renal injury. Animal studies of diseases damaging glomeruli suggest that they are involved in the initial inflammatory response within the kidney. In studies of patients with autoimmune diseases, such as systemic lupus erythematosus, elevated IL-17A levels and higher proportions of Th17 cells in circulating blood have been found, correlating with disease severity. Animal models of AKI have demonstrated that administration of an antibody against IL-17A reduces renal injury. Therefore, blockade of IL-17A/F signaling may be a promising avenue to explore in clinical trials as a novel therapy for the treatment and prevention of immune mediated renal diseases.
Original publication
Other news from the department science
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.